Simplify Logo

Full-Time

Inventory Specialist

Confirmed live in the last 24 hours

Umoja Biopharma

Umoja Biopharma

201-500 employees

Develops in vivo CAR T-cell therapies

Biotechnology
Healthcare

Compensation Overview

$23 - $27.9Hourly

+ Overtime

Mid

Lafayette, CO, USA

Required to be onsite 5 days a week.

Category
Administrative & Executive Assistance
Specialized Administrative Roles
Required Skills
Communications
Management
Data Analysis
Excel/Numbers/Sheets
Requirements
  • A GED or equivalent degree with 3 years of experience in inventory management, preferably in a GMP-regulated environment.
  • Advanced proficiency in Microsoft Excel, including expertise in pivot tables, VLOOKUP, and other data management functions.
  • Strong analytical skills and attention to detail.
  • Excellent organizational and problem-solving skills.
  • Ability to work independently and as part of a team.
  • Strong communication skills, both written and verbal.
  • Knowledge of GMP guidelines and their application in inventory management.
Responsibilities
  • Monitor and maintain stock levels through regular physical and system checks, ensuring accuracy and efficiency in inventory counts.
  • Utilize advanced Excel functions to create and manage detailed spreadsheets; experience with pivot tables and data analysis is crucial.
  • Implement and maintain inventory management systems to accurately track, record, and report inventory status.
  • Coordinate with procurement and warehouse departments to optimize inventory levels and replenish stock as needed.
  • Conduct regular audits to ensure compliance with GMP standards and internal policies.
  • Resolve discrepancies between inventory records and physical stock quickly and accurately.
  • Prepare detailed reports and forecasts related to inventory for upper management, highlighting potential issues and improvements.
  • Assist in developing and implementing improvements to existing inventory management procedures to increase efficiency and accuracy.
  • Operating the warehouse according to Umoja SOPs and Quality Systems.

Umoja Biopharma focuses on immunotherapy by reprogramming T cells in the body to target and destroy cancer cells. Unlike traditional methods that modify cells outside the body, Umoja's approach modifies the immune system in vivo, aiming for long-lasting remissions. The company primarily targets patients with solid tumors and hematological cancers that have not responded to other treatments. Its business model is based on developing and commercializing a proprietary CAR T-cell gene therapy platform that is scalable and can treat cancers at various stages. By producing off-the-shelf therapies in-house, Umoja can distribute its treatments more efficiently than those requiring individual customization. The goal is to enhance cancer treatment through effective use of the immune system.

Company Stage

Series B

Total Funding

$271M

Headquarters

Seattle, Washington

Founded

2019

Growth & Insights
Headcount

6 month growth

6%

1 year growth

15%

2 year growth

51%
Simplify Jobs

Simplify's Take

What believers are saying

  • The collaboration with AbbVie, valued at up to $1.44 billion, provides substantial financial backing and validation of Umoja's technology.
  • Umoja's appointment of experienced executives like Britton Russell as CFO indicates strong leadership capable of guiding the company through growth phases.
  • Being recognized as one of the thriving biotechs in Seattle underscores Umoja's prominence and potential in the biotech industry.

What critics are saying

  • The success of Umoja's in vivo CAR T-cell therapies is still contingent on clinical trial outcomes, which carry inherent uncertainties.
  • The competitive landscape in immunotherapy is intense, with numerous companies vying for market share, which could impact Umoja's growth.

What makes Umoja Biopharma unique

  • Umoja Biopharma's in vivo approach to reprogramming T cells is a significant departure from traditional ex vivo methods, offering a potentially more efficient and scalable solution.
  • Their proprietary CAR T-cell gene therapy platform is designed to be off-the-shelf, allowing for faster production and distribution compared to customized therapies.
  • Strategic partnerships with major players like AbbVie highlight Umoja's innovative edge and potential for significant market impact.